Company Overview - BioSig Technologies, Inc. has merged with Streamex Exchange Corporation and will change its name to Streamex Corp. effective September 12, 2025 [1] - The trading symbol will change to "STEX" on the Nasdaq Capital Market [1][2] - BioSig Technologies is a medical device technology company focused on advanced digital signal processing for cardiovascular treatments [4] - Streamex is a Real World Asset tokenization company that aims to bring gold and commodities markets on-chain [3] Corporate Actions - All stock trading and market-related information will be reported under the new symbol "STEX" starting September 12, 2025 [2] - The CUSIP number will remain unchanged, and no action is required from shareholders regarding the symbol change [2]

Group 1 - BioSig Technologies, Inc. has provided an update regarding the status of its merger with Streamex Exchange Corporation, indicating that the acquisition proposal will be adjourned pending final NASDAQ approval [1][3] - The merger transaction was officially closed on May 28, 2025, with 19.99% of BioSig shares already issuable to Streamex shareholders, while the remaining shares await NASDAQ approval [2][4] - The Board of Directors has decided to postpone Proposal No. 1 (the Acquisition Proposal) to a later date due to the pending NASDAQ approval, but all other proposals will proceed as planned at the Special Meeting on September 5, 2025 [3][4] Group 2 - Streamex is a company focused on RWA tokenization, aiming to create institutional-grade infrastructure for the gold and commodities market, supported by a gold-denominated treasury and tokenization technology [5] - BioSig Technologies specializes in medical device technology, particularly with its PURE EP™ Platform, which provides insights for electrophysiologists in the treatment of cardiovascular arrhythmias [6]

Group 1 - BioSig Technologies, Inc. has merged with Streamex Exchange Corporation, focusing on gold tokenization infrastructure for on-chain gold markets [1] - The company will participate in the 5th annual Needham Virtual Crypto 1x1 Conference on September 4, 2025, where its CEO and CIO will hold one-on-one meetings with institutional investors [1] - Streamex aims to build institutional-grade infrastructure for the gold market, supported by a gold-denominated treasury and tokenization technology [2] Group 2 - BioSig Technologies specializes in medical device technology, particularly with its PURE EP™ Platform that provides insights for electrophysiologists in treating cardiovascular arrhythmias [3]

Core Viewpoint - BioSig Technologies, Inc. has successfully closed an underwritten public offering to support its merger with Streamex Exchange Corporation, focusing on gold tokenization infrastructure [1][2][3]. Group 1: Offering Details - The offering included 3,852,149 shares of common stock priced at $3.90 per share, generating gross proceeds of approximately $15,023,381 before expenses [2]. - The net proceeds will be utilized for purchasing gold bullion, general corporate purposes, and working capital [2]. Group 2: Strategic Intent - The CEO of BioSig emphasized the importance of aligning short and long-term capital strategies with high-quality shareholders to enhance shareholder value [3]. - The company aims to establish itself as a leader in the gold bullion-based real-world asset space, leveraging the recent capital raise [3]. Group 3: Company Background - Streamex is focused on building institutional-grade infrastructure for gold tokenization, supported by a gold-denominated treasury [6]. - BioSig Technologies is a medical device company known for its PURE EP™ Platform, which aids electrophysiologists in treating cardiovascular arrhythmias [7][8].

Company Overview - BioSig Technologies, Inc. recently merged with Streamex Exchange Corporation, enhancing its market position in the gold tokenization sector [1][5] - BioSig is a medical device technology company specializing in advanced digital signal processing technology for electrophysiology [6][7] Public Offering Details - The company announced a public offering of 3,852,149 shares of common stock at a price of $3.90 per share, with expected gross proceeds of approximately $15,023,381.10 [1] - The offering is set to close on or around August 15, 2025, subject to customary closing conditions [1] Use of Proceeds - The net proceeds from the offering will be utilized for purchasing gold bullion, working capital, and general corporate purposes [1] Underwriters - Clear Street and Needham & Company are acting as joint book-running managers for the offering [2] Regulatory Compliance - The offering is made under a shelf registration statement declared effective by the SEC on December 17, 2024, with a final prospectus supplement to be filed [3]

Core Viewpoint - BioSig Technologies, Inc. has announced its intention to offer shares of common stock through an underwritten public offering, following its recent merger with Streamex Exchange Corporation [1] Group 1: Offering Details - The offering will include shares of common stock or pre-funded warrants, with the completion subject to market conditions [1] - The net proceeds from the offering are intended for purchasing gold bullion, working capital, and general corporate purposes [1] - Clear Street and Needham & Company are acting as joint book-running managers for the offering [2] Group 2: Regulatory Information - The offering is made pursuant to a shelf registration statement on Form S-3, declared effective by the SEC on December 17, 2024 [3] - A preliminary prospectus supplement will be filed with the SEC, and interested parties are encouraged to read the documents for more information [3] Group 3: Company Background - BioSig Technologies is a medical device technology company specializing in advanced digital signal processing technology for electrophysiology [6] - The PURE EP™ Platform developed by the company allows for real-time acquisition of raw signal data, enhancing procedural success in ablation treatments [7] - Streamex, a wholly owned subsidiary of BioSig, focuses on gold tokenization and building infrastructure for the gold market [5]

Core Insights - BioSig Technologies, Inc. has appointed Sean Roosen as Strategic Advisor to its wholly owned subsidiary, Streamex Exchange Corporation, following its acquisition in May 2025 [1] - Sean Roosen is a prominent figure in the mining industry with over 30 years of experience, having founded and led multiple successful resource ventures [2][3] - Streamex aims to revolutionize commodity markets through real-world asset tokenization, enhancing liquidity and accessibility in the financial sector [6][8] Company Overview - BioSig Technologies, Inc. is a medical device technology company known for its PURE EP™ Platform, which aids electrophysiologists in treating cardiovascular arrhythmias [9] - Streamex focuses on tokenizing real-world assets in the commodities space, developing infrastructure for primary issuance and exchange [6][8] Leadership and Expertise - Sean Roosen has a notable track record, including founding Osisko Development Corp. and leading Osisko Mining Corporation, which developed the Canadian Malartic mine [2][3] - The advisory board of Streamex includes other industry leaders, such as Frank Giustra, who has founded companies with significant market capitalizations [7] Strategic Vision - The company believes in the future of finance being driven by tokenization and decentralized markets, aiming to bridge traditional finance with the digital economy [8] - Roosen expressed enthusiasm about joining Streamex, highlighting the potential of bringing the resource sector into the digital age through tokenized assets [5]